TheraRadar
← Back
Data updated: Jul 17, 2026

VERA THERAPEUTICS INC.

Biotech
ImmunologyInfectious DiseaseDermatology Execution: Needs Improvement

VERA THERAPEUTICS INC. is a biotechnology company focused on Immunology, Infectious Disease, Dermatology.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)

VERA THERAPEUTICS INC.'s Key Drugs

VERA THERAPEUTICS INC.'s core commercial portfolio centers on TRUTAKNA, spanning Immunology and Infectious Disease — its most strategically important drugs approved in the last 15 years.

TRUTAKNA
Approved 2026

VERA THERAPEUTICS INC.'s Recent FDA Approvals

VERA THERAPEUTICS INC. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

TRUTAKNA BLA
2026-07-07
ataciept-vymj

VERA THERAPEUTICS INC.'s Therapeutic Areas

VERA THERAPEUTICS INC.'s approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 92%
0 drugs Phase 3: 8 Phase 2: 7
Infectious Disease 4%
0 drugs Phase 2: 1
Dermatology 4%
0 drugs Phase 2: 1

VERA THERAPEUTICS INC.'s Top Competitors

VERA THERAPEUTICS INC.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, BAUSCH AND LOMB INC, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Infectious Disease, Immunology, Dermatology
BAUSCH AND LOMB INC other
Infectious Disease, Dermatology, Immunology
APOTHECON specialty
Infectious Disease, Dermatology, Immunology
PHARMACIA AND UPJOHN big-pharma
Dermatology, Infectious Disease, Immunology
PF PRISM CV big-pharma
Infectious Disease, Dermatology, Immunology

VERA THERAPEUTICS INC. Pipeline Snapshot

VERA THERAPEUTICS INC. has 17 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 9 Phase 2 and 0 Phase 1.

8
Phase 3
9
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • TRUTAKNA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/2 completed
  • • Speed: N/A months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges